Showing 1 - 2 of 2
<Emphasis Type="Bold">Background: Market authorization does not guarantee patient access to any given drug. This is particularly true for costly orphan drugs because access depends primarily on co-payments, reimbursement policies and prices. The objective of this article is to identify differences in the availability...</emphasis>
Persistent link: https://www.econbiz.de/10011001693
Background: Market authorization does not guarantee patient access to any given drug. This is particularly true for costly orphan drugs because access depends primarily on co-payments, reimbursement policies and prices. The objective of this article is to identify differences in the availability...
Persistent link: https://www.econbiz.de/10010614375